MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

MiniMed (NASDAQ: MMED) announced an expanded agreement with Abbott to commercialize integrated dual glucose-ketone sensors designed to work exclusively with MiniMed smart dosing systems.

Rhea-AI Summary

MiniMed (NASDAQ: MMED) announced an expanded agreement with Abbott to commercialize integrated dual glucose-ketone sensors designed to work exclusively with MiniMed smart dosing systems.

The same-size-as-Instinct sensors aim to enable early, real-time ketone detection to help prevent diabetic ketoacidosis (DKA). Abbott’s dual systems have CE Mark, are under FDA review, and are not yet cleared or available in the United States.

Positive

• Expanded collaboration with Abbott on integrated dual glucose-ketone sensors
• Exclusive integration with MiniMed automated insulin delivery and Smart MDI systems
• Real-time ketone data designed to support earlier DKA risk alerts and intervention
• Sensors match the size of Instinct, described as the world’s smallest, thinnest sensor

Negative

• Abbott dual glucose-ketone systems are not yet cleared or available in the United States
• Regulatory and commercialization milestones remain pending, with sensors not yet available to users

Argus Jun 3 session

+15.93% close to close Open Argus

Details

News Market Reaction – MMED

In the Jun 3 session, MMED gained 15.93%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +15.9% in the session following this news. A strong positive reaction aligns with M...

Analysis

The stock surged +15.9% in the session following this news. A strong positive reaction aligns with MiniMed’s strategy of deepening its sensor ecosystem. The expanded Abbott collaboration on dual glucose‑ketone sensors enhances the value of its smart dosing platforms and addresses DKA risk, a critical clinical concern. However, past news flow showed mixed price follow-through on positive catalysts, so investors have historically reassessed enthusiasm after initial spikes.

Key Figures

DKA age group: Under age 58 Pediatric supervision age: Ages 2–6

DKA age group

Under age 58

Leading cause of death in type 1 diabetes patients under 58

Pediatric supervision age

Ages 2–6

MiniMed system use requires caregiver supervision in this age group

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   Product showcase

   24h Move

   -3.4%

   Plans to showcase MiniMed Flex and MiniMed Go at ADA scientific meeting.

2. May 26

   Conference participation

   24h Move

   -5.8%

   Announcement of participation in Goldman Sachs global healthcare conference.

3. May 21

   Clinical outcomes data

   24h Move

   +0.8%

   Trial showed consistent strong glycemic outcomes across sensors with 780G.

4. Apr 13

   Earnings date set

   24h Move

   +5.7%

   Scheduled Q4 and full-year 2026 earnings release and webcast details.

5. Mar 18

   FDA clearance

   24h Move

   -0.2%

   FDA cleared MiniMed Flex smartphone-controlled insulin pump ahead of schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

diabetic ketoacidosis, ketone monitoring, continuous ketone monitoring, ce mark, +3 more

7 terms

diabetic ketoacidosis medical

"These new dual monitoring sensors are designed to enable early, real-time detection of rising ketones to help prevent diabetic ketoacidosis (DKA)..."

Diabetic ketoacidosis is a serious, sudden complication of uncontrolled diabetes where the body, unable to use sugar for energy, breaks down fat and produces acidic chemicals called ketones, causing very high blood sugar, dehydration and a dangerous change in blood chemistry. It matters to investors because DKA drives hospital admissions, affects demand for diabetes medicines, devices and emergency care, and can influence clinical trial results, regulatory decisions and a company’s costs or liability exposure — like a sudden engine failure forcing expensive repairs.

ketone monitoring medical

"Today, ketone monitoring requires separate finger-stick blood tests or urine strips..."

Ketone monitoring is the regular measurement of ketones—small molecules the body produces when burning fat for energy—using blood, urine, or breath tests. For investors, it signals demand for medical devices, consumer wearables, testing supplies and clinical services because ketone levels guide treatment decisions in diabetes, ketogenic therapy and acute care; think of it as a fuel gauge that helps patients and clinicians avoid dangerous imbalances and tailor care.

continuous ketone monitoring medical

"Continuous ketone monitoring is important because it can detect rising ketones in real time..."

A wearable or implanted sensor system that measures levels of ketone bodies in the body continuously and sends real‑time readings to a display or app. Investors care because these devices can create recurring revenue from hardware, software and data services, affect medical adoption and reimbursement decisions, and signal market demand for metabolic health monitoring much like continuous glucose monitors did for diabetes management.

ce mark regulatory

"Abbott recently received CE Mark for its dual glucose-ketone system, which are also under FDA review."

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

fda review regulatory

"Abbott recently received CE Mark for its dual glucose-ketone system, which are also under FDA review."

FDA review is the formal evaluation by the U.S. Food and Drug Administration of a drug, medical device, or biologic to decide if it is safe and effective for use. For investors, it matters because the outcome determines whether a product can be sold in the U.S.; a positive review is like getting a building permit that allows commercial use, while delays or rejection can block revenue and change a company’s value.

insulin delivery system medical

"How will the dual glucose-ketone sensors work with MiniMed's insulin delivery system?"

A system that delivers insulin to a person with diabetes, ranging from simple pens and syringes to wearable pumps and automatic “closed‑loop” devices that use sensors to adjust doses. Investors care because these products drive recurring sales, can command higher prices for convenience or accuracy, and face clear regulatory and reimbursement hurdles—think of it as choosing between a basic appliance and a smart, subscription‑linked device that affects long‑term revenue and risk.

smart dosing systems technical

"The dual sensors will be fully integrated with MiniMed's smart dosing systems and is designed to provide continuous glucose and ketone data..."

Smart dosing systems are connected devices and software that monitor medication use and automatically adjust, schedule, or remind patients of doses—think of a thermostat that dispenses the right amount at the right time. They matter to investors because they can improve treatment outcomes, reduce waste and hospital visits, create recurring revenue from hardware or data services, and face regulatory and reimbursement dynamics that affect market adoption and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management

NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.

These new dual monitoring sensors are designed to enable early, real-time detection of rising ketones to help prevent diabetic ketoacidosis (DKA), a life-threatening complication.¹ The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott, and will offer MiniMed users expanded choice across its automated insulin delivery and Smart MDI systems. The sensors will be the same size as the Instinct sensor, the world's smallest and thinnest sensor.^2,3

"By integrating dual glucose-ketone monitoring sensors with our MiniMed smart dosing systems, we're adding an additional layer of intelligence and protection," said Que Dallara, chief executive officer, MiniMed. "Our system is designed to keep people in tight glucose control and minimize DKA risk through smarter, more consistent automation — intervening before it ever becomes an emergency. This partnership with Abbott takes that commitment even further. At MiniMed, our mission is to make every day a better day for people with diabetes, and that means relentlessly pursuing innovations that not only improve outcomes but also deliver genuine peace of mind."

DKA is responsible for hundreds of thousands of hospitalizations annually in the United States and remains the leading cause of death in children and adults under age 58 with type 1 diabetes.¹ The complication occurs when the body doesn't have enough insulin to use blood sugar as energy, and instead begins breaking down fat for fuel, leading to a buildup of acid-like ketones. Ketones can rise independently of glucose levels and, in some cases, even when glucose appears in range – which can delay detection of DKA risk.⁴ Today, ketone monitoring requires separate finger-stick blood tests or urine strips — often performed only after symptoms have already appeared, when intervention is most urgent and outcomes are less certain.

The companies expect to provide further updates on regulatory and commercialization milestones in the coming months.

Abbott's dual glucose-ketone systems are not yet cleared or available for sale in the United States.

Frequently Asked Questions:

How will the dual glucose-ketone sensors work with MiniMed's insulin delivery system?
The dual sensors will be fully integrated with MiniMed's smart dosing systems and is designed to provide continuous glucose and ketone data directly to its intelligent dosing algorithm. While the glucose data informs real-time automated insulin delivery decisions, the ketone data adds an additional layer of safety by enabling earlier alerts when ketone levels begin to rise above a safe level — potentially enabling intervention before DKA develops.

What is DKA and why is continuous ketone monitoring important?
Diabetic ketoacidosis (DKA) is a serious, life-threatening complication of diabetes that occurs when the body produces dangerously high levels of ketones (acid molecules) due to insufficient insulin. DKA is the leading cause of death in children and adults under age 58 with type 1 diabetes and accounts for hundreds of thousands of hospitalizations each year.¹ Continuous ketone monitoring is important because it can detect rising ketones in real time — before symptoms appear — enabling earlier intervention and potentially preventing emergency hospitalization.

Who would the dual sensors potentially be indicated for?
We anticipate the dual glucose-ketone sensors would be available for the same users indicated to use MiniMed systems today. This includes those with type 1 or insulin-requiring type 2 diabetes using MiniMed AID systems, and those with type 1 or type 2 diabetes using MiniMed Go.^†

Is the sensor available?
Not yet. Abbott recently received CE Mark for its dual glucose-ketone system, which are also under FDA review. Additional details on the partnership will be shared in the coming months.

†Proper pairing, connectivity, and settings required or incorrect dosing and serious injury can occur. Ages 2-6 require caregiver supervision. See user guide for full details.

1. Umpierrez, et al. Diabetes Care (2024): https://doi.org/10.2337/dci24-0032. 

2. Among patient-applied sensors.

3. Data on file. Abbott Diabetes Care, Inc.

4. Dhatariya, et al. Lancet Diabetes & Endocrinology (2025): https://pubmed.ncbi.nlm.nih.gov/41381175/. 

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's filings with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-expand-sensor-portfolio-with-integrated-dual-glucose-ketone-sensors-made-by-abbott-302789583.html

SOURCE MiniMed

FAQ

What did MiniMed (NASDAQ: MMED) announce on June 3, 2026?

MiniMed announced an expanded agreement with Abbott to commercialize dual glucose-ketone sensors integrated with its smart dosing systems. According to MiniMed, these sensors aim to provide continuous glucose and ketone data to support tighter glucose control and reduce diabetic ketoacidosis (DKA) risk.

How will the dual glucose-ketone sensors work with MiniMed MMED smart dosing systems?

The dual sensors are designed to fully integrate with MiniMed smart dosing systems, sending continuous glucose and ketone data to the dosing algorithm. According to MiniMed, glucose data guides automated insulin delivery, while ketone data adds safety by triggering earlier alerts when ketone levels rise.

Why is continuous ketone monitoring important for MiniMed MMED users at risk of DKA?

Continuous ketone monitoring can detect rising ketones in real time before symptoms appear, enabling earlier intervention. According to MiniMed, DKA is a life-threatening complication and a leading cause of death in people under 58 with type 1 diabetes, driving demand for earlier detection.

Who might be indicated to use MiniMed MMED dual glucose-ketone sensors?

MiniMed anticipates indications similar to its current systems, including people with type 1 or insulin-requiring type 2 diabetes using MiniMed automated insulin delivery, and those with type 1 or type 2 diabetes using MiniMed Go. According to MiniMed, proper pairing and settings are required for safe use.

Are the MiniMed and Abbott dual glucose-ketone sensors available in the United States?

The dual sensors are not yet available. According to MiniMed, Abbott recently received CE Mark for its dual glucose-ketone system, which remains under FDA review, and Abbott’s dual systems are not cleared or available for sale in the United States at this time.

What regulatory and commercialization milestones are expected next for MiniMed MMED dual sensors?

MiniMed and Abbott plan to share further updates on regulatory and commercialization milestones in the coming months. According to MiniMed, Abbott’s dual glucose-ketone system already has CE Mark and is currently undergoing FDA review, but no launch timeline has been disclosed.